7. Mishra TK, Rath PK. The role of aldosterone and selective aldosterone receptor antagonist eplerenone in cardiovascular disease. JIACM, 2006;7(3):211-6
8. Qavi AH, Kamal R, Schrier RW. Clinical use of diuretics in heart failure, cirrhosis and nephrotic syndrome. Int J of Nephrol, 2015; article ID 975934, 9 pages.
9. Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. The Am J of Cardiol, 2005;96(12):10-18
10. Luo W, Meng Y, Ji HL, et al. Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS ONE, 2012;7(3):e34230
11. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. CJASN, 2010;5(6):1132-1140
12. Rathnayake D, Sinlclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatologic clinics, 2010;28(3):611-618
13. Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol, 2017;3(2):111-115
14. Berardesca E, Gabba P, Ucci G, et al. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React, 1988;10(2):115-9
15. Bagherani N. Efficacy of topical spironolactone in treatment of acne. Dermatologic therapy, 2015, 28(176)
16. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart failure reviews, 2005;10(1):23-29
17. MIMS. Spironolactone. 2022. https://www.mims.com/indonesia/drug/info/spironolactone/?type=brief&mtype=generic